4.3 Review

SHARP: enabling generation of real-world evidence on a pan-European scale to improve the lives of individuals with severe asthma

Journal

ERJ OPEN RESEARCH
Volume 7, Issue 2, Pages -

Publisher

EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00064-2021

Keywords

-

Funding

  1. European Respiratory Society
  2. GlaxoSmithKline Research and Development Limited
  3. Chiesi Farmaceutici SPA
  4. Novartis Pharma AG
  5. Sanofi-Genzyme Corporation
  6. Teva Branded Pharmaceutical Products RD, Inc.

Ask authors/readers for more resources

Real-world evidence is crucial for addressing unanswered questions in severe asthma, and the SHARP collaboration aims to conduct research and clinical studies on a pan-European scale using data from national registries and asthma centers. With innovative design and technological advancements, SHARP hopes to impact the lives of patients with severe asthma in a positive way.
Real-world evidence is important to help unravel unanswered problems in severe asthma and is valuable to better understand the patient experience and common clinical practice. The Severe Heterogeneous Asthma Registry, Patient-centred (SHARP) Clinical Research Collaboration is created as a network of national registries and severe asthma centres that work together to perform registry based real-world research and clinical studies on a pan-European scale. Such collaboration requires a new, innovative design to overcome the many issues that arise with largescale data collection across national borders. SHARP has developed a platform that offers a federated analysis approach where national registry data are transformed and integrated into a common data model (CDM). The CDM then allows a local analysis of de-identified patient data and subsequent aggregate (meta-)analysis. To facilitate an easily accessible way to set up new registries, SHARP enables new registries to take part in a central database, based on already proven technology. Next to being economical, this linkage ensures data from different SHARP central members to be comparable. Technological advancements lead to an ever-expanding rate of patient data that will be collected; with the collective effort of the pan-European severe asthma research community SHARP hopes to ensure that they are well equipped to enter a new era of medical research, with the ultimate goal to positively impact the lives of patients with severe asthma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available